ACTRN12613000261718招募中2 期
A phase IIa double-blind, randomised, placebo-controlled study investigating the efficacy and safety of GlycOmega PLUS supplementation in the treatment of osteoarthritis of the knee.
Aroma New Zealand Limited0 个研究点目标入组 110 人开始时间: 2013年3月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 40 Years 至 85 Years（—）
- 性别
- All
入选标准
- •Age 40 years and older with clinical evidence of painful knee (osteoarthritis) OA for at least 6 months (with a pain numerical scale of 4 and above at baseline) and radiographic evidence of knee OA as determined as having a kellgren-Lawrence grade 2- or 3-. Not taking any dietary supplements including fish oils, glucosamine, green-lipped mussel, herbal preparations, antibiotics and probiotics 4 weeks before commencing trial.
排除标准
- •knee replacements(s) of affected knee with OA; intra-articular therapies (knee cortisone injection and arthroscopy) within 3 months of starting the trial; pregnancy; use of illicit drugs; alcohol abuse; shell fish allergy; uncontrolled chronic health conditions i.e. diabetes, hypertension, cardiovascular disease; the inability to with-hold from using non-steroidal antiinflammatory drugs (NSAIDs) for the duration of the trial
研究者
相似试验
尚未招募
2 期
A Phase 2a study to assess efficacy and safety of VIT-2763 in subjects with sickle cell diseasesickle cell diseasesickle cell disease (SCD) (sickle haemoglobin (HbS)/S or HbS/ßT0genotype)LBCTR2021064783Vifor (International) Inc.25
进行中（未招募）
1 期
A study to evaluate the efficacy of KH176 in patients with a genetically confirmed mitochondrial DNA mutation. Patients to be allocated randomly to placebo or investigational drug in different periods; meaning each patient will receive both placebo as well as the investigational drug. Assignment of actual treatment order will be unknown to patient and doctor.A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation (including but not limited to MELAS, MIDD and mixed compositions).EUCTR2019-000599-40-GBKhondrion B.V.27
进行中（未招募）
1 期
A study to evaluate the efficacy of KH176 in patients with a genetically confirmed mitochondrial DNA mutation. Patients to be allocated randomly to placebo or investigational drug in different periods; meaning each patient will receive both placebo as well as the investigational drug. Assignment of actual treatment order will be unknown to patient and doctor.EUCTR2019-000599-40-NLKhondrion B.V.27
进行中（未招募）
1 期
A study to evaluate the efficacy of KH176 in patients with a genetically confirmed mitochondrial DNA mutation. Patients to be allocated randomly to placebo or investigational drug in different periods; meaning each patient will receive both placebo as well as the investigational drug. Assignment of actual treatment order will be unknown to patient and doctor.A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation (including but not limited to MELAS, MIDD and mixed compositions).MedDRA version: 22.0Level: PTClassification code 10052641Term: Mitochondrial DNA mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-000599-40-DKKhondrion B.V.27
进行中（未招募）
1 期
A study to evaluate the efficacy of KH176 in patients with a genetically confirmed mitochondrial DNA mutation. Patients to be allocated randomly to placebo or investigational drug in different periods; meaning each patient will receive both placebo as well as the investigational drug. Assignment of actual treatment order will be unknown to patient and doctor.A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) transfer ribonucleic acid (tRNA)Leu(UUR) m.3243A>G mutation (including but not limited to MELAS, MIDD and mixed compositions).MedDRA version: 22.0Level: PTClassification code 10052641Term: Mitochondrial DNA mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2019-000599-40-DEKhondrion B.V.27